Research press release





今回、James Croweたちは、過去にジカウイルスに感染したことのある人々の白血球からヒト抗体を単離し、予備検査によって特に強力と考えられる抗体に注目し、この抗体をジカウイルス感染症のマウスモデルで検証した。妊娠マウスをジカウイルスに感染させ、ウイルス感染前後のいずれかの時点で抗体を与える実験がそれぞれ行われ、いずれの場合も母マウスと胎仔のジカウイルス量が減り、胎盤損傷の程度が小さくなり、胎仔のサイズが大きくなった。


A new antibody therapy may prevent fetal damage in pregnant mice infected with the Zika virus, a Nature paper suggests. Owing to differences in gestational features between mice and humans, further studies are needed to determine whether the findings can be translated to the clinic, but it is hoped that the discovery will help to inform vaccine design efforts.

Zika virus infection is known to cause neurological problems including Guillain-Barre syndrome in adults and microcephaly in unborn children. In February 2016, this prompted the World Health Organization to declare the current epidemic a Public Health Emergency of International Concern.

James Crowe and colleagues isolated human antibodies from the white blood cells of people who had previously been infected with Zika virus, then focused on one that seemed particularly potent in preliminary tests. They tested the antibody in a mouse model of Zika virus infection. In separate experiments, pregnant mice received the treatment either before or after viral infection. In both cases, viral load was reduced in mother and unborn offspring, there was less damage to the placenta and fetuses were bigger.

The results hint that the treatment might be useful both as a preventative measure and also after an animal has been infected with the virus. This evidence showing that anti-viral therapy can prevent or control Zika virus infection in pregnancy in mice highlights the possibility of meaningful interventions during this time.

doi: 10.1038/nature20564

「Nature 関連誌注目のハイライト」は、ネイチャー広報部門が報道関係者向けに作成したリリースを翻訳したものです。より正確かつ詳細な情報が必要な場合には、必ず原著論文をご覧ください。

メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週最新のNature 関連誌のハイライトを皆様にお届けいたします。